WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 315142

CAS#: 1051375-16-6 (free)

Description: Dolutegravir, also known as GSK1349572, is a potent inhibitor of HIV integrase with an IC50 value of 2.7 nM for HIV-1 integrase-catalyzed strand transfer in vitro.1 It inhibits HIV-1 viral replication (EC50 = 0.51 nM) in peripheral blood mononuclear cells (PBMCs). Dolutegravir (DTG) is an antiretroviral medication used, together with other medication, to treat HIV/AIDS. It may also be used, as part of post exposure prophylaxis, to prevent HIV infection following potential exposure.

Chemical Structure

CAS# 1051375-16-6 (free)

Theoretical Analysis

MedKoo Cat#: 315142
Name: Dolutegravir
CAS#: 1051375-16-6 (free)
Chemical Formula: C20H19F2N3O5
Exact Mass: 419.12928
Molecular Weight: 419.38
Elemental Analysis: C, 57.28; H, 4.57; F, 9.06; N, 10.02; O, 19.08

Size Price Shipping out time Quantity
25mg USD 150 Same day
50mg USD 250 Same day
200mg USD 650 Same day
500mg USD 1050 Same day
1g USD 1450 Same day
2g USD 1950 Same day
5g USD 2850 Same day
10g USD 4650 Same day
Inquire bulk and customized quantity

Pricing updated 2021-03-08. Prices are subject to change without notice.

Dolutegravir (GSK1349572), purity > 98%, is in stock. The same day shipping out after order is received.

Related CAS #: 1051375-19-9 (sodium)   1051375-16-6 (free)    

Synonym: Dolutegravir; GSK1349572; GSK-1349572; GSK 1349572; Tivicay; S/GSK1349572.

IUPAC/Chemical Name: (4R,12aS)-N-(2,4-difluorobenzyl)-7-hydroxy-4-methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide


InChi Code: InChI=1S/C20H19F2N3O5/c1-10-4-5-30-15-9-24-8-13(17(26)18(27)16(24)20(29)25(10)15)19(28)23-7-11-2-3-12(21)6-14(11)22/h2-3,6,8,10,15,27H,4-5,7,9H2,1H3,(H,23,28)/t10-,15+/m1/s1

SMILES Code: O=C(C1=CN(C2=C(O)C1=O)C[C@]3([H])OCC[C@@H](C)N3C2=O)NCC4=CC=C(F)C=C4F

Solid powder

>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO.

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:

Preparing Stock Solutions

The following data is based on the product molecular weight 419.38 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: Llibre JM, Clotet B. Once-daily single-tablet regimens: a long and winding road to excellence in antiretroviral treatment. AIDS Rev. 2012 Jul;14(3):168-78. PubMed PMID: 22833060.

2: Rhodes MC, Laffan S, Genell C, Gower J, Maier C, Fukushima T, Nichols G, Eaton Bassiri A. Assessing a Theoretical Risk of Dolutegravir-Induced Developmental Immunotoxicity in Juvenile Rats. Toxicol Sci. 2012 Jul 12. [Epub ahead of print] PubMed PMID: 22790968.

3: Adams JL, Greener BN, Kashuba AD. Pharmacology of HIV integrase inhibitors. Curr Opin HIV AIDS. 2012 Jul 19. [Epub ahead of print] PubMed PMID: 22789987.

4: Lennox JL. The use of HIV-1 integrase inhibitors in antiretroviral naive patients. Curr Opin HIV AIDS. 2012 Jul 19. [Epub ahead of print] PubMed PMID: 22789985.

5: Shamroe CL, Bookstaver PB, Rokas KE, Weissman SB. Update on raltegravir and the development of new integrase strand transfer inhibitors. South Med J. 2012 Jul;105(7):370-8. PubMed PMID: 22766666.

6: Saladini F, Meini G, Bianco C, Monno L, Punzi G, Pecorari M, Borghi V, Di Pietro M, Filice G, Gismondo MR, Micheli V, Penco G, Carli T, De Luca A, Zazzi M; for the ARCA Collaborative Group. Prevalence of HIV-1 integrase mutations related to resistance to dolutegravir in raltegravir naïve and pretreated patients. Clin Microbiol Infect. 2012 May 28. doi: 10.1111/j.1469-0691.2012.03917.x. [Epub ahead of print] PubMed PMID: 22716970.

7: Quashie PK, Sloan RD, Wainberg MA. Novel therapeutic strategies targeting HIV integrase. BMC Med. 2012 Apr 12;10:34. Review. PubMed PMID: 22498430; PubMed Central PMCID: PMC3348091.

8: Nguyen HL, Ruxrungtham K, Delaugerre C. Genetic barrier to the development of resistance to integrase inhibitors in HIV-1 subtypes CRF01_AE and B. Intervirology. 2012;55(4):287-95. Epub 2012 Mar 23. PubMed PMID: 22456540.

9: Chen S, Min SS, Peppercorn A, Borland J, Lou Y, Song I, Fujiwara T, Piscitelli SC. Effect of a single supratherapeutic dose of dolutegravir on cardiac repolarization. Pharmacotherapy. 2012 Apr;32(4):333-9. doi: 10.1002/j.1875-9114.2012.01033.x. Epub 2012 Mar 15. PubMed PMID: 22422361.

10: Katlama C, Murphy R. Dolutegravir for the treatment of HIV. Expert Opin Investig Drugs. 2012 Apr;21(4):523-30. Epub 2012 Mar 2. Review. PubMed PMID: 22380682.

Additional Information

Dolutegravir, also known as GSK1349572, is an FDA-approved drug for the treatment of HIV infection. It can be used to treat HIV-infected adults who have never taken HIV therapy (treatment-naïve) and HIV-infected adults who have previously taken HIV therapy (treatment-experienced), including those who have been treated with other integrase strand transfer inhibitors. Tivicay is also approved for children ages 12 years and older weighing at least 40 kilograms (kg) who are treatment-naïve or treatment-experienced but have not previously taken other integrase strand transfer inhibitors.